When historians examine the AI agent boom of the mid-2020s, the decisive contest may turn out to have been won not by the most powerful general-purpose model, but by the most specialised one. Nowhere is that dynamic more visible than in healthcare—and the trend is unmistakably global.
The number of companies building AI agents explicitly for the healthcare sector grew from just 7 to 47 between March and November 2025—a nearly sevenfold increase in under eight months, according to CB Insights data. That acceleration is not confined to the United States. Parallel waves are building in the United Kingdom, Germany, Singapore, India, and across the Gulf Cooperation Council, where government-backed digital health initiatives have made hospitals unusually receptive to AI-native vendors.
Why Regulation Becomes a Global Competitive Moat
Healthcare is not a friendly environment for generic software in any jurisdiction. In the United States, HIPAA compliance sets the baseline; in Europe, the AI Act and the General Data Protection Regulation layer additional obligations on top of legacy medical device directives; in Singapore and Australia, evolving health data sovereignty rules further complicate deployment. A general-purpose AI agent is poorly positioned to navigate any one of these labyrinths, let alone all of them simultaneously.
A chatbot that hallucinates in a consumer context is an embarrassment; one that does so in a clinical workflow is a legal liability—and potentially a patient safety event. That compliance burden, paradoxically, becomes a durable competitive advantage for specialists. A startup that has invested in jurisdiction-specific data pipelines, clinical validation workflows, and the institutional trust of hospital procurement committees has built something genuinely difficult to replicate—even for a better-funded generalist rival operating out of a tech hub thousands of miles away.
The regulatory moat is real, and global capital markets are pricing it accordingly. European health-tech investors have accelerated deal activity in clinical AI since the AI Act's medical provisions came into sharper focus, while Gulf sovereign wealth funds have directed portions of their AI mandates toward compliant healthcare infrastructure rather than horizontal model development.
Cybersecurity: The Same Script, Every Time Zone
Healthcare is not alone in rewarding specialisation. AI-related cybersecurity mergers and acquisitions reached record levels in 2025, and CB Insights rates cybersecurity AI agent startups as the sector most primed for exit, based on acquisition probability modelling. Companies such as Nullify and Strike Ready carry acquisition probability scores above 70%—unusually high signals that suggest strategic acquirers from multiple continents are actively circling.
The parallel is instructive. Like healthcare, cybersecurity operates under mounting regulatory pressure worldwide: from SEC disclosure requirements in the United States, to the EU's NIS2 Directive and DORA financial resilience framework, to emerging critical infrastructure mandates across Southeast Asia and the Middle East. Generic AI tools lack the domain knowledge to interpret threat intelligence through the lens of local regulatory obligations or sector-specific attack surfaces. Purpose-built agents—trained on threat data from specific verticals and fine-tuned for compliance reporting—fill that gap in ways that horizontal platforms structurally cannot.
A Shift in the Global AI Investment Thesis
CB Insights projects that the private AI agent market will move toward greater specialisation over the 2025–2027 period, with industry-specific solutions gaining ground against horizontal platforms. If that forecast holds—and early deal flow suggests it will—the valuation gap between vertical and horizontal AI agents will likely widen, and exit multiples in healthcare and cybersecurity could command a statistically significant premium regardless of geography.
For enterprise buyers from London to Lagos to Seoul evaluating AI agent deployments, the calculus is shifting. The era of deploying a single general-purpose model across every workflow is giving way to a more deliberate procurement logic: identify the highest-stakes, most heavily regulated processes first, and deploy the most specialised agent available. In a world where regulatory complexity is accelerating faster than any single AI platform can track, the specialist is becoming the safest bet—and the most valuable acquisition target.
Sources:
1 Yahoo Finance, "1 Hypergrowth Tech Stock to Buy in 2026" (March 03, 2026)
2 Yahoo Finance, "German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In" (February 23, 2026)
3 Yahoo Finance, "FutureGen Industries Announces Open Market Investments" (March 23, 2026)
4 Yahoo Finance, "Varex Imaging Says Demand Steady Despite Geopolitics; Tariff Relief to Lift Margins, India Ramp Ahea" (March 22, 2026)
5 Globe Newswire, "ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel" (March 23, 2026)